Oncology Central

Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2- metastatic breast cancer


Aim: To examine cost and mortality differences in postmenopausal women with HR+/HER2- advanced breast cancer. Methods: Using claims data (2007–2013), women with newly diagnosed (de novo) stage IV, or early- or late-recurring metastatic breast cancer were identified. Results: Compared with de novo (n = 121) and late-recurrent (n = 106), early-recurrent (n = 172) patients had significantly higher costs in total and for anticancer systemic agents.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.